Latest period
$7.41B
YoY change
-20.6%
5Y CAGR
+27.6%
Peak year (2022)
$19.12B
Latest annual
$8.65B
Total Equity history chart for Moderna (MRNA) from 2016 to 2025
Latest: $8.65B
Total Equity growth chart for Moderna (MRNA) from 2016 to 2025
Latest: -20.6%
Total Equity history table for Moderna (MRNA) from 2016 to 2025
| 2025 | $8.65B | -20.6% | −$2.25B | ||
| 2024 | $10.90B | -21.3% | −$2.95B | ||
| 2023 | $13.85B | -27.6% | −$5.27B | ||
| 2022 | $19.12B | +35.2% | +$4.98B | ||
| 2021 | $14.14B | +452.3% | +$11.58B | ||
| 2020 | $2.56B | +118.0% | +$1.39B | ||
| 2019 | $1.17B | -23.2% | −$355.43M | ||
| 2018 | $1.53B | +144.7% | +$904.95M | ||
| 2017 | $625.30M | -25.7% | −$216.56M | ||
| 2016 | $841.85M | — | — |
- 2025$8.65B-20.6%
- 2024$10.90B-21.3%
- 2023$13.85B-27.6%
- 2022$19.12B+35.2%
- 2021$14.14B+452.3%
- 2020$2.56B+118.0%
- 2019$1.17B-23.2%
- 2018$1.53B+144.7%
- 2017$625.30M-25.7%
- 2016$841.85M—
Total Equity values are taken from Moderna's reported balance sheets (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Total Equity at Moderna (MRNA)
According to Moderna's latest reported financial statements, the company's latest reported total equity is $7.41B. Net assets — also called stockholders' equity — equal total assets minus total liabilities. They represent the residual claim of shareholders on the company's assets and roughly track book value over time.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
In 2025, Moderna (MRNA) total equity totalled $8.65B – declined 20.6% year-over-year.
Through 2020–2025 (5 years), Moderna total equity delivered a +27.6% annualised rate; with mixed annual results across the window.
Between 2022 and 2025, Moderna total equity plunged 54.8%, falling from $19.12B to $8.65B.
The record annual total equity stands at $19.12B, reached in 2022; the historical low of $625.30M was recorded in 2017.
Moderna Total Equity by Year
Moderna Total Equity 2025: $8.65B
In 2025, Moderna reported total equity of $8.65B, declined 20.6% below 2024.
Moderna Total Equity 2024: $10.90B
Moderna total equity in 2024 was $10.90B, declined 21.3% below 2023.
Moderna Total Equity 2023: $13.85B
2023's total equity for Moderna came in at $13.85B, declined 27.6% below 2022.
Moderna Total Equity 2022: $19.12B
Moderna posted total equity of $19.12B in 2022, surged 35.2% from 2021. This figure represents the highest annual value in the available history.
Moderna Total Equity 2021: $14.14B
Moderna total equity in 2021 was $14.14B.
See more financial history for Moderna (MRNA).
Sector peers by Total Equity
Healthcare peers of Moderna (MRNA), ranked by their latest total equity
| $94.11B | |
| $81.54B | |
| $52.61B | |
| $48.67B | |
| $30.52B | |
| $26.54B | |
| $8.66B | |
| −$3.27B |
- $94.11B
- $81.54B
- $52.61B
- $48.67B
- $30.52B
- $26.54B
- $8.66B
- −$3.27B
Frequently asked questions
Moderna (MRNA) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation